Table 2.

Utilization patterns of index LLM among monotherapy initiators at 12- and 36-month follow-up

Utilization patterns	12-month follow-up		36-month follow-up
	n	%	n	%
Number of monotherapy initiators	47,587	100	21,198	100
Dose titration assessment
Up-titration of index LLM	4,180	8.8	2,635	12.4
Down-titration of index LLM	1,462	3.1	793	3.7
No dose change of index LLM	41,945	88.1	17,770	83.8
Discontinuation/persistence
Discontinued index LLM	25,938	54.5	16,488	77.8
Days from index fill date to first discontinuation date, mean (SD), mediana	116 (91)	90	270 (274)	155
Persistence of index LLM (days), mean (SD), mediana	219 (133)	242	449 (412)	275
Switch
Switched to non-index LLMs	4,579	9.6	2,935	13.8
Days from index fill date to first switch date, mean (SD), mediana	129 (88)	101	293 (278)	173
Augmentation
Augmented index LLM	1,403	2.9	586	2.8
Days from index fill date to first augmentation, mean (SD), mediana	157 (92)	157	310 (299)	194

Note:

^aData presented as mean (SD), median.

Abbreviation: LLM, lipid-lowering medication.